Lung cancer trial tests immune booster with chemo and radiation
NCT ID NCT02525757
First seen Jun 24, 2026 · Last updated Jul 17, 2026 · Updated 3 times
Summary
This study tests whether adding the drug MPDL3280A (a type of immunotherapy) to standard chemotherapy and radiation is safe for people with advanced non-small cell lung cancer that cannot be surgically removed. About 52 participants will receive the combination and be monitored for side effects and how long their cancer stays under control. The goal is to see if this approach can improve outcomes without causing too many severe side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- MPDL3280A (atezolizumab) combined with carboplatin, paclitaxel, and radiation therapy
- What this could lead to
- If successful, this could point toward a safer and more effective treatment plan for people with advanced lung cancer that cannot be removed by surgery.
- What could go wrong
- This is a small, early-phase study with only 52 participants, so results may not apply to everyone. Adding MPDL3280A to standard therapy could increase side effects like immune-related inflammation.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
MD Anderson Cancer Center
Houston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a simple CT scan catch lung cancer earlier in kuwait?
- Can a new immunotherapy combo outsmart advanced lung cancer?
- Can a new drug combo revive Immunotherapy's power against resistant tumors?
- Double attack on mutant KRAS: can two targeted drugs outsmart resistant cancers?
- Seeing the fight: new imaging tracer may reveal how immune cells attack lung cancer
- Could a bronchial wash detect lung cancer mutations faster?